Sanofi Announces Availability of Dupixent® (dupilumab) for Adults with Moderate-to-Severe Atopic Dermatitis in Malaysia
Sanofi announced that the Ministry of Health has granted market approval for Dupixent® (dupilumab), for use in adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.